SCHEMBL1122195

SCHEMBL1122195

O=C(O)N1CCc2ccccc2C1c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HHAT Q5VTY9 3/20 0.60
PRCP P42785 2/20 0.59
CHRM3 P20309 3/20 0.58
CHRM2 P08172 2/20 0.58
CHRM1 P11229 2/20 0.58
CYP2D6 P10635 1/20 0.58
CACNA1F O60840 1/20 0.58
CHRM4 P08173 1/20 0.58
CHRM5 P08912 1/20 0.58
KCNE1 P15382 1/20 0.58
KCNQ1 P51787 1/20 0.58
CACNA1D Q01668 1/20 0.58
KCNH2 Q12809 1/20 0.58
CACNA1S Q13698 1/20 0.58
CACNA1C Q13936 1/20 0.58
SCN5A Q14524 1/20 0.58
KCND3 Q9UK17 1/20 0.58
HDAC8 Q9BY41 2/20 0.57
HDAC3 O15379 1/20 0.54
HDAC1 Q13547 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12226990 1.00 HHAT (0.60) HHATPRCPCHRM3CHRM2CHRM1
SCHEMBL698295 1.00 HHAT (0.60) HHATPRCPCHRM3CHRM2CHRM1
SCHEMBL4250247 1.00 HHAT (0.60) HHATPRCPCHRM3CHRM2CHRM1
Bromide SCHEMBL4631703 0.98 HHAT (0.58) HHATPRCPCHRM3CHRM2CHRM1
Hydrochloric Acid SCHEMBL8903394 0.98 HHAT (0.58) HHATPRCPCHRM3CHRM2CHRM1
Oxalic Acid SCHEMBL2995637 0.97 HHAT (0.57) HHATPRCPCHRM3CHRM2CHRM1
Succinic Acid SCHEMBL6822306 0.93 CHRM3 (0.62) HHATPRCPCHRM3CHRM2CHRM1
Succinic Acid SCHEMBL2849101 0.93 CHRM3 (0.62) HHATPRCPCHRM3CHRM2CHRM1
SCHEMBL4632573 0.92 HHAT (0.59) HHATPRCPCHRM3CHRM2CHRM1
Cadaverine Tartrate SCHEMBL5985676 0.92 CYP2D6 (0.58) HHATPRCPCHRM3CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9399624-B2 Process for preparing (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) 2016-07-26 US claimed
EP-2029587-B1 PROCESS FOR THE PREPARATION OF SOLIFENACIN ZENTIVA AS (CZ) 2015-09-02 EP claimed
US-20150225348-A1 PROCESS FOR PREPARING (1S)-1-PHENYL-3,4-DIHYDRO-2(1H)-ISOQUINOLINE-CARBOXYLATE Shangyu Jingxin Pharmaceutical Co., Ltd. (CN) 2015-08-13 US claimed
US-8772491-B2 Process for the preparation of solifenacin succinate AUROBINDO PHARMA LTD (IN) 2014-07-08 US claimed
US-20130123502-A1 NOVEL PROCESS FOR THE PREPARATION OF SOLIFENACIN SUCCINATE AUROBINDO PHARM LTD. (IN) 2013-05-16 US claimed
EP-2305676-B1 Synthesis of solifenacin monosuccinate ASTELLAS PHARMA INC (JP) 2012-10-17 EP claimed
WO-2012001481-A1 NOVEL PROCESS FOR THE PREPARATION OF SOLIFENACIN SUCCINATE AUROBINDO PHARMA LIMITED (IN) 2012-01-05 WO claimed
EP-2094693-B1 A METHOD FOR THE PREPARATION OF SOLIFENACIN ZENTIVA KS (CZ) 2011-11-16 EP claimed
US-20110264760-A1 METHOD AND APPARATUS PROVIDING FOR OUTPUT OF A CONTENT PACKAGE BY AN APPLICATION BASED AT LEAST IN PART ON A CONTENT TYPE SELECTION AND ONE OR MORE CONTEXTUAL CHARACTERISTICS NOKIA CORPORATION 2011-10-27 US claimed
US-8034942-B2 Process for the preparation of solifenacin Zentiva k s. (CZ) 2011-10-11 US claimed
EP-1405638-B1 PHARMACEUTICAL COMPOSITION COMPRISING QUINUCLIDIN-3'-YL 1-PHENYL-1,2,3,4,-TETRAHYDROISOQUINOLINE-2-CARBOXYLATE FOR TREATMENT OF INTERSTITIAL CYSTITIS AND/OR ABACTERIAL PROSTATITIS ASTELLAS PHARMA INC (JP) 2011-02-09 EP claimed
US-20100145055-A1 METHOD FOR THE PREPARATION OF SOLIFENACIN ZENTIVA K.S. (CZ) 2010-06-10 US claimed
WO-2010051996-A1 COMBINED USE OF AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST AND AN ANTI-MUSCARINIC AGENT ASTELLAS IRELAND CO., LTD. (IE) 2010-05-14 WO claimed
EP-2094693-A2 A METHOD FOR THE PREPARATION OF SOLIFENACIN Zentiva, k.s. (CZ) 2009-09-02 EP claimed
US-20090203914-A1 PROCESS FOR THE PREPARATION OF SOLIFENACIN ZENTIVA K.S. (CZ) 2009-08-13 US claimed
EP-2029587-A2 PROCESS FOR THE PREPARATION OF SOLIFENACIN Zentiva, A.S. (CZ) 2009-03-04 EP claimed
WO-2008077357-A2 A METHOD FOR THE PREPARATION OF SOLIFENACIN ZENTIVA, A.S. (CZ) 2008-07-03 WO claimed
WO-2007147374-A2 PROCESS FOR THE PREPARATION OF SOLIFENACIN ZENTIVA A.S. (CZ) 2007-12-27 WO claimed
EP-3463312-A1 DOSING REGIMENS FOR BETA-3 ADRENOCEPTOR AGONISTS AND ANTI-MUSCARINIC AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER Velicept Therapeutics, Inc. (US) 2019-04-10 EP disclosed
EP-0801067-A1 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1997-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123502-A1 NOVEL PROCESS FOR THE PREPARATION OF SOLIFENACIN SUCCINATE SUCNR1, SUCLG2, SUCLA2 HHAT 2645/4885PRCP 2004/4885CHRM3 33/4885
US-20100145055-A1 METHOD FOR THE PREPARATION OF SOLIFENACIN CHRNA3, CHRM3, CHRNA1 HHAT 782/4885PRCP 2138/4885CHRM3 2/4885
US-20150225348-A1 PROCESS FOR PREPARING (1S)-1-PHENYL-3,4-DIHYDRO-2(1H)-ISOQUINOLINE-CARBOXYLATE IDH3A, POLG, IDH3B HHAT 4453/4885PRCP 2271/4885CHRM3 1644/4885
US-20090203914-A1 PROCESS FOR THE PREPARATION OF SOLIFENACIN OPRL1, CHRNG, CHRM1 HHAT 4097/4885PRCP 960/4885CHRM3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.